Neoprobe Elects Gordon Troup Chairman Of The Board
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Gordon A. Troup was elected Chairman of the Board at a meeting of the Board of Directors held following the Company’s 2011 Annual Meeting of Stockholders. Mr. Troup succeeds Carl J. Aschinger, Jr., who has served as a director of our Company since June 2004 and as Chairman of the Board since July 2007.
"Gordon is an innovative, forward-thinking leader and has been a positive influence for the Company since joining the Board, and I am very pleased that he succeeds me as Chairman," Mr. Aschinger said. "He has played an important role in helping evaluate our growth strategy and in guiding us during this pivotal period in our Company’s history. His experience will serve the Company well as Neoprobe continues its transformation into a pure-play specialty radiopharmaceutical development and commercialization entity."
"In my time with Neoprobe, I have witnessed the beginning of an evolution of an entrepreneurial company with a niche medical device business and development stage radiopharmaceuticals into a company poised to become a lead player in the radiopharmaceutical space," Mr. Troup said. "Carl’s leadership and stewardship are evident in the enormous accomplishments at Neoprobe during the last several years and I thank him for his tremendous contribution as we look forward to getting Lymphoseek ® over the goal line of FDA approval."
Mr. Troup has served as a director of Neoprobe since July 2008 and as Vice Chairman of the Board since July 2010. He served as President of the Nuclear Pharmacy Services business at Cardinal Health, Inc. (Cardinal Health), a multinational medical products and services company, from January 2003 until his retirement in December 2007. Mr. Troup joined Cardinal Health in 1990 and was appointed Group President of Pharmaceutical Distribution and Specialty Distribution Services in 1999. Prior to joining Cardinal Health, Mr. Troup was employed for ten years by American Hospital Supply Corporation and three years by Zellerbach Paper, a Mead Company. Mr. Troup has a B.S. degree in Business Management from San Diego State University.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV